2023
AUG
09
LimmaTech Biologics will be attending the 23rd International Pathogenic Neisseria Conference in Boston from 24 through 29 September 2023.
AUG
09
LimmaTech Biologics will be attending the Vaccines Europe 2023 in Berlin from 14 through 15 September 2023.
Dr Paula Carranza to present
JUL
20
LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth
LimmaTech has leveraged a novel technology platform to produce a pipeline of vaccines against multi-resistant bacterial infections that present global health threats
JUL
20
GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine
LimmaTech in-licenses Shigella bioconjugate vaccine from GSK to continue its clinical development; Phase I/II study completion and results are expected in 2023
MAY
31
LimmaTech Biologics will be attending the Bio International Convention in Boston from 5 through 8 June 2023.
MAY
10
LimmaTech Biologics will be attending the Bio€quity Europe 2023 in Dublin from 14 through 16 May 2023.
Dr Patricia Martin to present
MAR
15
LimmaTech Biologics will be attending the Swiss Biotech Day in Basel from 24 through 25 April 2023.
Dr Patricia Martin to present
MAR
15
LimmaTech Biologics will be attending the Swiss Nordic Bio 2023 in Zurich on 30 March 2023.
MAR
15
LimmaTech Biologics will be attending the BIO-Europe Spring in Basel from 20 through 22 March 2023.
JAN
13
LimmaTech Biologics will be attending the Vaccines as tools to combat antimicrobial resistance congress in Birmingham from 27 through 28 February 2023.
Dr Cristina Alaimo to present
JAN
13
LimmaTech Biologics will be attending the World Vaccine Congress in Washington from 3 through 6 April 2023.